Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Oct 24, 2022 11:10am
127 Views
Post# 35043616

RE:RE:RE:RE:Example of PR for Proof Of Concept

RE:RE:RE:RE:Example of PR for Proof Of ConceptWake up Biobob! She did not have to exercise these options until late May of next year. She took a tax hit early to send us all a positive message - she had every incentive from a tax perspective to wait  until next year to exercise those options but did not. She is sending a message so listen up. The market will not be stupid forever.

Biobob wrote: Wel then it is great news that she thinks theat Th is worth at least 26 cents + the tax liability that goest with it.. lets rejoice on this festive news... and the market response is as usual a new low on dismal volume... now that we are priced  in the Hersey bar territory and that we compare on PE basis to coal companies we can tell ourselves what this management has accomplished with their rocket science.  


<< Previous
Bullboard Posts
Next >>